204 related articles for article (PubMed ID: 25060604)
1. Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.
Cho SK; Kim CO; Park ES; Chung JY
Br J Clin Pharmacol; 2014 Dec; 78(6):1426-32. PubMed ID: 25060604
[TBL] [Abstract][Full Text] [Related]
2. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants.
Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY
Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793
[TBL] [Abstract][Full Text] [Related]
3. The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.
Ding Y; Jia Y; Song Y; Lu C; Li Y; Chen M; Wang M; Wen A
Eur J Clin Pharmacol; 2014 Feb; 70(2):141-6. PubMed ID: 24170325
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1.
Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H
Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927
[TBL] [Abstract][Full Text] [Related]
5. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
6. The effects of rabeprazole on metformin pharmacokinetics and pharmacodynamics in Chinese healthy volunteers.
Liu G; Wen J; Guo D; Wang Z; Hu X; Tang J; Liu Z; Zhou H; Zhang W
J Pharmacol Sci; 2016 Dec; 132(4):244-248. PubMed ID: 27245553
[TBL] [Abstract][Full Text] [Related]
7. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions.
Ahlin G; Chen L; Lazorova L; Chen Y; Ianculescu AG; Davis RL; Giacomini KM; Artursson P
Pharmacogenomics J; 2011 Dec; 11(6):400-11. PubMed ID: 20567254
[TBL] [Abstract][Full Text] [Related]
8. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers.
Morrissey KM; Stocker SL; Chen EC; Castro RA; Brett CM; Giacomini KM
Clin Pharmacokinet; 2016 Apr; 55(4):495-506. PubMed ID: 26507723
[TBL] [Abstract][Full Text] [Related]
10. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis.
Jin HE; Hong SS; Choi MK; Maeng HJ; Kim DD; Chung SJ; Shim CK
Pharm Res; 2009 Mar; 26(3):549-59. PubMed ID: 19002567
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.
Hibma JE; Zur AA; Castro RA; Wittwer MB; Keizer RJ; Yee SW; Goswami S; Stocker SL; Zhang X; Huang Y; Brett CM; Savic RM; Giacomini KM
Clin Pharmacokinet; 2016 Jun; 55(6):711-21. PubMed ID: 26597253
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.
Flory J; Haynes K; Leonard CE; Hennessy S
Br J Clin Pharmacol; 2015 Feb; 79(2):330-6. PubMed ID: 25199921
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Shu Y; Brown C; Castro RA; Shi RJ; Lin ET; Owen RP; Sheardown SA; Yue L; Burchard EG; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2008 Feb; 83(2):273-80. PubMed ID: 17609683
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.
Morse BL; Fallon JK; Kolur A; Hogan AT; Smith PC; Hillgren KM
AAPS J; 2021 Apr; 23(3):58. PubMed ID: 33903987
[TBL] [Abstract][Full Text] [Related]
15. Effects of proton pump inhibitors on metformin pharmacokinetics and pharmacodynamics.
Kim A; Chung I; Yoon SH; Yu KS; Lim KS; Cho JY; Lee H; Jang IJ; Chung JY
Drug Metab Dispos; 2014 Jul; 42(7):1174-9. PubMed ID: 24764147
[TBL] [Abstract][Full Text] [Related]
16. A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study.
Chung H; Oh J; Yoon SH; Yu KS; Cho JY; Chung JY
PLoS One; 2018; 13(1):e0191258. PubMed ID: 29342199
[TBL] [Abstract][Full Text] [Related]
17. A Drug-Drug Interaction Study to Evaluate the Impact of Rimegepant on OCT2- and MATE1-Mediated Transport of Metformin in Healthy Participants.
Bhardwaj R; Morris B; Matschke K; Bertz R; Croop R; Liu J
Clin Pharmacol Drug Dev; 2024 May; 13(5):465-473. PubMed ID: 38174905
[TBL] [Abstract][Full Text] [Related]
18. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
Shu Y; Sheardown SA; Brown C; Owen RP; Zhang S; Castro RA; Ianculescu AG; Yue L; Lo JC; Burchard EG; Brett CM; Giacomini KM
J Clin Invest; 2007 May; 117(5):1422-31. PubMed ID: 17476361
[TBL] [Abstract][Full Text] [Related]
19. mPEG
Zhang Y; Sun M; Jian S; Huang J; Xiao C; Zhang X; Hu R; Si L
Mol Pharm; 2021 Jul; 18(7):2586-2599. PubMed ID: 34102842
[TBL] [Abstract][Full Text] [Related]
20. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
